Skip to Main Content

Advertisement

Skip Nav Destination

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

December 30, 2021
Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid leukemia.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement